Ensysce Biosciences, Inc.ENSCNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank75
5Y CAGR-5.2%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-5.2%/yr
Long-term compound
Percentile
P75
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 31.06% |
| Q2 2025 | -58.54% |
| Q1 2025 | -123.46% |
| Q4 2024 | 25.11% |
| Q3 2024 | 55.83% |
| Q2 2024 | 32.23% |
| Q1 2024 | -89.16% |
| Q4 2023 | 20.36% |
| Q3 2023 | 27.21% |
| Q2 2023 | 13.82% |
| Q1 2023 | -9.45% |
| Q4 2022 | 50.92% |
| Q3 2022 | -51.21% |
| Q2 2022 | -29.20% |
| Q1 2022 | 8.78% |
| Q4 2021 | 1.49% |
| Q3 2021 | -897.91% |
| Q2 2021 | 25.88% |
| Q1 2021 | 3.13% |
| Q4 2020 | -249.13% |
| Q3 2020 | 40.54% |
| Q2 2020 | -100.19% |
| Q1 2020 | 1096.84% |
| Q4 2019 | 2221.87% |
| Q3 2019 | 16.91% |
| Q2 2019 | 242.31% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 291.45% |
| Q1 2018 | 12.16% |
| Q4 2017 | 0.00% |
| Q3 2017 | 0.00% |